TABLE 3

Primary and Secondary Outcomes in a Randomized, Placebo-Controlled Trial on Oral Zinc as Adjunct Therapy for Severe Pneumonia in Children 2 to 35 Months of Age

Zinc GroupPlacebo GroupHazard Ratioa (95% CI)P
nValue (IQR)nValue (IQR)
Median time to cessation of severe pneumonia in hours28849 (33, 77)29249 (29, 91)1.10 (0.94 – 1.30).22
Proportion with duration of severe pneumonia in hoursRisk Ratiob (95% CI)
 >7229583 (28)297104 (35)0.80 (0.63–1.02).07
 >9629456 (19)29664 (22)0.88 (0.64–1.21).44
 >12029331 (11)29446 (16)0.67 (0.44–1.03).07
Proportion with treatment failure29698 (33)298111 (37)0.88 (0.71–1.10).29
Proportion with vomiting after supplementc29941 (14)29926 (9)1.57 (0.99–2.50).05
  • IQR, interquartile range.

  • a Hazard ratio for time until cessation of severe pneumonia was estimated by using Cox proportional hazards models. A value of >1 indicates beneficial effect of zinc.

  • b From generalized linear models with a log link function and binomial distribution.

  • c After the first dose.